Dongdong Zhang

Mr. Dongdong Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
DZDongdong Zhang
Dongdong Zhang
ZWZhaoye Wang
Zhaoye Wang
JLJin and Li
Jin and Li
JZJianbo Zhu
Jianbo Zhu

8 December 2022 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
TZTieying Zhang
Tieying Zhang
DZDongdong Zhang
Dongdong Zhang
SFshi feng
shi feng


6 May 2022 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
DZDongdong Zhang
Dongdong Zhang
TZTieying Zhang
Tieying Zhang
JZJianbo Zhu
Jianbo Zhu
JLJin and Li
Jin and Li

13 April 2022 in Research Square
Verified
Preprint
Open access
PDF file
XGXingchen Guo
Xingchen Guo
WGWanhao Gao
Wanhao Gao
DZDongdong Zhang
Dongdong Zhang
MLMuwei Li
Muwei Li
Objective To evaluate the therapeutic effects of traditional Chinese medicines Radix astragali (Huangqi, HQ), Ginseng (Renshen, RS), Radix puerariae (Gegen, GG), and Mulberry leaf (Sangye, SY) on diabetic cardiomyopathy (DC) based on bioinformatics and network pharmacology, through gene expression analysis of geo clinical samples, molecular docking of compounds and targets, and molecular dynamics simulation, and to discover new targets for prevention or treatment of DC, in order to facilitate and better serve the discovery of new drugs as well as their application in the clinic. Materials and methods For the initial selection of ingredients and targets using the TCMSP as a starting point, we performed a primary screening of ingredients and targets of the four herbs using tools including Cytoscape, Tbtools, R 4.0.2, Autodock Vina, PyMOL, and GROMACS. To further screen the effective ingredients and targets, we performed protein interaction network (PPI) analysis (gene = 12), gene expression analysis (n = 24) by clinical samples of DCs from the gse26887 dataset, biological process (BP) analysis (FDR ≤ 0.05, gene = 7), KEGG pathway analysis (FDR ≤ 0.05, gene = 7), and ingredient target pathway network analysis (gene = 7) by applying these targets from the screen, Biological processes, disease pathways regulated by targets and the relationship between each component target and pathway were obtained. We further screened the targets and visualized the docking results by precision molecular docking of ingredients and targets, after which we performed molecular dynamics simulation and consulted a large number of relevant literatures for validation of the results. Results Through screening, analysis and validation of the data, we finally confirmed the presence of 36 active ingredients in HQ, RS, GG, and SY, which mainly act on AKT1, ADRB2, GSK3B, PPARG, and BCL2 targets, and these five targets mainly regulate PI3K-Akt, Adrenergic signaling in cardiomyocytes, AGE-RAGE signaling pathway in diabetic complications, JAK-STAT, cGMP-PKG, AMPK, and mTOR signaling pathway exert preventive or therapeutic effects on DCM. Molecular dynamics (MD) simulations revealed that the complex formed by Calycosin, Frutinone A, Puerarin, Inophyllum E, the four active components of HQ, RS, GG, and SY, and the four target proteins ADRB2, PPARG, AKT1, and GSK3B acting on DCS is able to exist in a very stable tertiary structure under human environment. Conclusions our study successfully explains the effective mechanism of HQ, RS, GG, and SY in ameliorating DC, while predicting the potential targets and active components of HQ, RS, GG, and SY in treating DC, which provides a new basis for investigating novel mechanisms of action at the network pharmacology level and a great support for subsequent DC research.

29 December 2022
Verified
Journal Article
Open access
PDF file
XGXing-Chen Guo
Xing-Chen Guo
WGWan-Hao Gao
Wan-Hao Gao
ZZZhi-Wen Zhang
Zhi-Wen Zhang
DZDongdong Zhang
Dongdong Zhang
MLMu-Wei Li
Mu-Wei Li
Objective: To evaluate the therapeutic effects of traditional Chinese medicines Radix astragali (Huangqi, HQ), Ginseng (Renshen, RS), Radix puerariae (Gegen, GG), and Mulberry leaf (Sangye, SY) on diabetic cardiomyopathy (DC) based on bioinformatics and network pharmacology, through gene expression analysis of geo clinical samples, molecular docking of compounds and targets, and molecular dynamics simulation, and to discover new targets for prevention or treatment of DC, in order to facilitate and better serve the discovery of new drugs as well as their application in the clinic. Materials and Methods: For the initial selection of ingredients and targets using the TCMSP as a starting point, we performed a primary screening of ingredients and targets of the four herbs using tools including Cytoscape, Tbtools, R 4.0.2, Autodock Vina, PyMOL, and GROMACS. To further screen the effective ingredients and targets, we performed protein interaction network (PPI) analysis (gene = 12), gene expression analysis (n = 24) by clinical samples of DCs from the gse26887 dataset, biological process (BP) analysis (FDR ? 0.05, gene = 7), KEGG pathway analysis (FDR ? 0.05, gene = 7), and ingredient target pathway network analysis (gene = 7) by applying these targets from the screen, Biological processes, disease pathways regulated by targets and the relationship between each component target and pathway were obtained. We further screened the targets and visualized the docking results by precision molecular docking of ingredients and targets, after which we performed molecular dynamics simulation and consulted a large number of relevant literature for validation of the results. Results: Through screening, analysis and validation of the data, we finally confirmed the presence of 36 active ingredients in HQ, RS, GG, and SY, which mainly act on AKT1, ADRB2, GSK3B, PPARG, and BCL2 targets, and these five targets mainly regulate PI3K-Akt, Adrenergic signaling in cardiomyocytes, AGE-RAGE signaling pathway in diabetic complications, JAK-STAT, cGMP-PKG, AMPK, and mTOR signaling pathway exert preventive or therapeutic effects on DCM. Molecular dynamics (MD) simulations revealed that the complex formed by Calycosin, Frutinone A, Puerarin, Inophyllum E, the four active components of HQ, RS, GG, and SY, and the four target proteins ADRB2, PPARG, AKT1, and GSK3B acting on DCS is able to exist in a very stable tertiary structure under human environment. Conclusion: Our study successfully explains the effective mechanism of HQ, RS, GG, and SY in ameliorating DC, while predicting the potential targets and active components of HQ, RS, GG, and SY in treating DC, which provides a new basis for investigating novel mechanisms of action at the network pharmacology level and a great support for subsequent DC research.